Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk (S6.001)

Benjamin Trewin; Mirasol Forcadela; Chiara Rocchi; Jessica Qiu; Melissa Chu; Niroshan Jeyakumar; Fionna Dela Cruz; Jane Andersen; Pakeeran Siriratnam; Antonia McLean; Deepti Yagnik; Nathaniel Lizak; Fiona Chan; Todd Hardy; Anneke van der Walt; Jeannette Lechner-Scott; Helmut Butzkueven; Simon Broadley; Michael Barnett; Stephen Reddel; Fabienne Brilot; Russell Dale; Saif Huda; Tomas Kalincik; S Ramanathan

doi:10.1212/wnl.0000000000216431

Key Points

This research aims to evaluate how effective maintenance immunotherapies are in preventing relapses and disability in MOGAD patients.
Determined effectiveness of various maintenance immunotherapies for MOGAD.
Assessed dose thresholds and their relationship with treatment outcomes.
Evaluated time dependence of therapies on relapse and disability rates.
Maintenance immunotherapies significantly reduced relapses in MOGAD patients compared to baseline.
Certain dose thresholds were identified as critical for maximizing treatment effectiveness.
Early administration of steroids provided a notable benefit in lowering the risk of confirmed sustained disability (CSD).

Implication

Determines effectiveness of maintenance immunotherapy in MOGAD, highlighting dose thresholds and disability risk.

Abstract

To determine the effectiveness, dose thresholds, and time dependence of maintenance immunotherapies for preventing relapse and confirmed sustained disability (CSD) in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disorder (MOGAD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Trewin et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f056498 https://doi.org/10.1212/wnl.0000000000216431

View at Publisher

Ask AI

Bookmark

Share

Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk (S6.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk (S6.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology